202 related articles for article (PubMed ID: 11583316)
1. Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis.
Sirolli V; Strizzi L; Di Stante S; Robuffo I; Procopio A; Bonomini M
Thromb Haemost; 2001 Sep; 86(3):834-9. PubMed ID: 11583316
[TBL] [Abstract][Full Text] [Related]
2. Effect of two different dialysis membranes on leukocyte adhesion and aggregation.
Hernandez MR; Palomo M; Fuste B; Carbó C; Collado S; Cases A; Escolar G
Nephron Clin Pract; 2007; 106(1):c1-8. PubMed ID: 17347577
[TBL] [Abstract][Full Text] [Related]
3. Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients.
Ashman N; Macey MG; Fan SL; Azam U; Yaqoob MM
Nephrol Dial Transplant; 2003 Oct; 18(10):2088-96. PubMed ID: 13679485
[TBL] [Abstract][Full Text] [Related]
4. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia.
Elshamaa MF; Elghoroury EA; Helmy A
Blood Coagul Fibrinolysis; 2009 Jun; 20(4):230-9. PubMed ID: 19521197
[TBL] [Abstract][Full Text] [Related]
5. Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk.
Aggarwal A; Kabbani SS; Rimmer JM; Gennari FJ; Taatjes DJ; Sobel BE; Schneider DJ
Am J Kidney Dis; 2002 Aug; 40(2):315-22. PubMed ID: 12148104
[TBL] [Abstract][Full Text] [Related]
6. Platelet surface receptor activation in patients with chronic renal failure on hemodialysis, peritoneal dialysis and those with successful kidney transplantation.
Ballow A; Gader AM; Huraib S; Al-Husaini K; Mutwalli A; Al-Wakeel J
Platelets; 2005 Feb; 16(1):19-24. PubMed ID: 15763892
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of biocompatibility of hemophane, cellulose diacetate and acrilonitile membranes in hemodialysis].
Germin Petrović D
Acta Med Croatica; 2004; 58(1):31-6. PubMed ID: 15125391
[TBL] [Abstract][Full Text] [Related]
8. Platelet function in patients on long term peritoneal dialysis.
Lindsay RM; Friesen M; Koens F; Linton AL; Oreopoulos D; de Veber G
Clin Nephrol; 1976 Aug; 6(2):335-9. PubMed ID: 954241
[TBL] [Abstract][Full Text] [Related]
9. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and kinetics of the synthesis and release of platelet-activating factor (PAF) by polyacrylonitrile membranes.
Guastoni C; Tetta C; Hoenich NA; Gervasio R; Sereni L; Tessore E; Wratten ML; Civati G
Clin Nephrol; 1996 Aug; 46(2):132-8. PubMed ID: 8869791
[TBL] [Abstract][Full Text] [Related]
11. Cell activation and cellular-cellular interactions during hemodialysis: effect of dialyzer membrane.
Sirolli V; Ballone E; Di Stante S; Amoroso L; Bonomini M
Int J Artif Organs; 2002 Jun; 25(6):529-37. PubMed ID: 12117292
[TBL] [Abstract][Full Text] [Related]
12. Platelet activation on hemodialysis: influence of dialysis membranes.
Cases A; Reverter JC; Escolar G; Sanz C; Lopez-Pedret J; Revert L; Ordinas A
Kidney Int Suppl; 1993 Jun; 41():S217-20. PubMed ID: 8320925
[TBL] [Abstract][Full Text] [Related]
13. The complement factor properdin induces formation of platelet-leukocyte aggregates via leukocyte activation.
Ruef J; Kuehnl P; Meinertz T; Merten M
Platelets; 2008 Aug; 19(5):359-64. PubMed ID: 18791942
[TBL] [Abstract][Full Text] [Related]
14. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor.
Ward JR; Bingle L; Judge HM; Brown SB; Storey RF; Whyte MK; Dower SK; Buttle DJ; Sabroe I
Thromb Haemost; 2005 Oct; 94(4):831-8. PubMed ID: 16270639
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis.
Aggarwal A; Whitaker DA; Rimmer JM; Solomon RJ; Gennari FJ; Sobel BE; Schneider DJ
Nephrol Dial Transplant; 2004 Jun; 19(6):1559-63. PubMed ID: 15034156
[TBL] [Abstract][Full Text] [Related]
16. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment.
Stasko J; Galajda P; Ivanková J; Hollý P; Rozborilová E; Kubisz P
Clin Appl Thromb Hemost; 2007 Oct; 13(4):410-5. PubMed ID: 17911193
[TBL] [Abstract][Full Text] [Related]
17. Platelet dysfunction and end-stage renal disease.
Kaw D; Malhotra D
Semin Dial; 2006; 19(4):317-22. PubMed ID: 16893410
[TBL] [Abstract][Full Text] [Related]
18. "In vitro" inhibition of platelet aggregation by uremic middle molecules.
Gallice P; Fournier N; Crevat A; Saingra S; Frayssinet R; Murisasco A; Sicardi F
Biomedicine; 1980; 33(6):185-8. PubMed ID: 7213919
[TBL] [Abstract][Full Text] [Related]
19. Biocompatibility of cellulosic and synthetic membranes assessed by leukocyte activation.
Hernández MR; Galán AM; Cases A; Lopez-Pedret J; Pereira A; Tonda R; Bozzo J; Escolar G; Ordinas A
Am J Nephrol; 2004; 24(2):235-41. PubMed ID: 15031626
[TBL] [Abstract][Full Text] [Related]
20. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis.
van Wyk V; Badenhorst PN; Kotzé HF
Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
